LHRHa

Phase 3Small molecule

Johnson & Johnson

LHRHa is one of 97 small molecule programs targeting Cognitive impairment. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cognitive ImpairmentActive, not recruiting

Prostate CancerActive, not recruiting

Prostatic NeoplasmsActive, not recruiting

Cognitive ImpairmentPreclinical

Active, not recruiting

Prostate CancerPhase 3

Active, not recruiting

Prostatic NeoplasmsPhase 3

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

LHRHa

Johnson & Johnson

Phase 3

2 2

Novantrone

Pfizer

Preclinical

5 3

Mekinist

Novartis

Preclinical

3 4

Trexall

Alnylam Pharmaceuticals

Preclinical

—5

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 6

Viagra

VViatris Specialty LLC

Preclinical

1 7

Duragesic

CCephalon

Preclinical

1 8

Prednisone/prednisolone

Roche

Preclinical

3 9

Triptorelin Pamoate

Ipsen

Preclinical

2 10

Ifex

BBaxter Healthcare Corporation

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2031

Phase 3Active, not recruiting

Prostatic Neoplasms

NCT04557059

Clinical

Trials by Indication[1]

Prostate Cancer2 trials

Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer

Completed·CCougar Biotechnology, Inc.·Phase 2·NCT01088529·66 enrolled

Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer

Active, not recruiting·UUniversity of Sydney·Phase 3·NCT02446444·802 enrolled

Abiraterone Acetate1 trial

Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01946165·69 enrolled

Cognitive impairment1 trial

Mild Cognitive Impairment in Men Following Androgen Deprivation

Withdrawn·IImperial College London·N/A·NCT01691976

Prostatic Neoplasms1 trial

A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer, Assessed by PSMA-PET With an Observational Cohort

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT04557059·692 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for LHRHa. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LHRHa compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LHRHa. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Johnson & Johnson

LHRHa

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2031

Trials by Indication[1]

Prostate Cancer2 trials

Abiraterone Acetate1 trial

Cognitive impairment1 trial

Prostatic Neoplasms1 trial

References

Drug Info

Quick Facts

Related News